Acorda therapeutics announces agreement for sale of manufacturing operations and long-term global supply agreement for inbrija®, corporate restructuring, and enters into “at the market” offering agreement

Ardsley, n.y.--(business wire)--acorda therapeutics, inc. (nasdaq: acor) today announced that it has entered into a definitive agreement to sell its inbrija manufacturing operations in chelsea, massachusetts to catalent for $80 million in cash. in connection with the sale, acorda and catalent have entered into a long-term global supply agreement under which catalent will manufacture and package inbrija for acorda, ensuring an uninterrupted drug supply for acorda's patients and continued adheren
ACOR Ratings Summary
ACOR Quant Ranking